Advancing gastric cancer treatment: A comprehensive review of hyperthermic intraperitoneal chemotherapy’s role and outcomes

Table 3 Therapeutic use of hyperthermic intraperitoneal chemotherapy, randomized controlled trials: Treatments and outcomes

Year	Ref./trial	Hyperthermic intraperitoneal chemotherapy protocol	Completeness of cytoreduction score (CC 0-1)	Neodjuvant Cht	Neoadjuvant treatment regimen	Adjuvant Cht	Adjuvant treatment regimen	Median OS (month)	1 year OS	2 years OS	3 years OS	Median relapse-free survival (month)
2011	Yang et al[27]	Cisplatin 120 mg + mitomycin C 30 mg for 60-90 minutes	CRS-A: 58.8% (20 of 34), CRS-H: 58.8% (20 of 34)	No	No	Yes	ND	CRS-A: 6.5 months vs CRS-H: 11.0 months	CRS-A: 29.4% vs CRS-H: 41.2%	CRS-A: 5.9% vs CRS-H: 14.7%	CRS-A: 0% vs CRS-H: 5.9%	ND
2014	Rudloff/GYMSSA	Oxaliplatin 460 mg/m2 for 30 minutes. Prior to perfusion: 5-fluorouracil 400 mg/m2 IV and leucovorin 20 mg/m2 IV	CRS-H: 88.8% (8 of 9)	Yes. GYMS arm (n = 6/9), SA arm (n = 7/8)	ND	Yes	FOLFOXIRI	SA arm: 4.3 months vs GYMS arm: 11.3 months	SA arm: 0% vs GYMS arm: 44%	SA arm: 0% vs GYMS arm: 22%	SA arm: 0% vs GYMS arm: 22%	ND
2023	Rau/GASTRIPEC-I	Mitomycin C 15 mg/m2 + cisplatin 75 mg/m2 for 60 minutes	CRS-A: 41.5% (22 of 53), CRS-H: 53.8% (28 of 52)	Yes (all)	HER-2+: Cisplatin, capecitabine, trastuzumab; HER-2-: Epirubicin, oxaliplatin, capecitabine	Yes	HER-2+: Cisplatin, capecitabine, trastuzumab; HER-2-: Epirubicin, oxaliplatin, capecitabine or fluorouracil, leucovorin, oxaliplatin, and docetaxel	CRS-A: 14.9 months vs CRS-H: 14.9 months	CRS-A: 60.5% vs CRS-H: 58.2%	CRS-A: 15.4% vs CRS-H: 25.5%	CRS-A: 0% vs CRS-H: 13.6%	CRS-A: 3.5 months vs CRS-H: 7.1 months

CRS-A: Cytoreductive surgery alone; CRS-H: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy; Cht: Chemotherapy; GYMS: Hyperthermic intraperitoneal chemotherapy + systemic FOLFOXIRI; HER-2: Human epidermal growth factor receptor 2; ND: Not declared; OS: Overall survival; SA: FOLFOXIRI alone.